Biotech Values

[oldberkeley]

>Recent Biotech Buyouts at a Large Premium<

Dew-

I'd certainly like to see a better numbers person than I do this, but...

While KOSN's buyout price was a 233% premium to the previous day's close, it was a 57% premium to the 200 day MA.

While COLY's buyout price was a 167% premium to the previous day's close, it was a 33% premium to the 200 day MA.

I stopped there (too much darn work, I have beer to drink! ) but I suspect that with some exceptions, one would find the same pattern.

I'm certainly no statistician, but this might support the thesis that many of these buyout premiums are not quite as dramatic as they appear.